المؤلفون: Monge, Susana, Humphreys, James, Nicolay, Nathalie, Braeye, Toon, Van Evercooren, Izaak, Holm Hansen, Christian, Emborg, Hanne‐Dorthe, Sacco, Chiara, Mateo‐Urdiales, Alberto, Castilla, Jesús, Martínez‐Baz, Iván, de Gier, Brechje, Hahné, Susan, Meijerink, Hinta, Kristoffersen, Anja Bråthen, Machado, Ausenda, Soares, Patricia, Nardone, Anthony, Bacci, Sabrina, Kissling, Esther, Nunes, Baltazar

المساهمون: European Centre for Disease Prevention and Control

المصدر: Influenza and Other Respiratory Viruses ; volume 18, issue 4 ; ISSN 1750-2640 1750-2659

الوصف: Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID‐19 hospitalisation and death in booster‐eligible ≥ 65‐year‐olds, during October–November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID‐19 hospitalisation and death was, respectively, 67% (95%CI: 58–74) and 67% (95%CI: 42–81) in 65‐ to 79‐year‐olds and 66% (95%CI: 57–73) and 72% (95%CI: 51–85) in ≥ 80‐year‐olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA.

الإتاحة: https://doi.org/10.1111/irv.13292Test

المؤلفون: Giannini, Edoardo G., Pasta, Andrea, Pieri, Giulia, Plaz Torres, Maria Corina, Marseglia, Mariarosaria, Pelizzaro, Filippo, Sangiovanni, Angelo, Cabibbo, Giuseppe, Ghittoni, Giorgia, Di Marco, Mariella, Foschi, Francesco Giuseppe, Guarino, Maria, Biasini, Elisabetta, Saitta, Carlo, Campani, Claudia, Svegliati‐Baroni, Gianluca, Gasbarrini, Antonio, Brunetto, Maurizia Rossana, Magalotti, Donatella, Azzaroli, Francesco, Mega, Andrea, Sacco, Rodolfo, Nardone, Gerardo, Sacerdoti, David, Masotto, Alberto, Vidili, Gianpaolo, Bucci, Laura, Vitale, Alessandro, Trevisani, Franco

المصدر: Liver International ; volume 44, issue 7, page 1588-1599 ; ISSN 1478-3223 1478-3231

الوصف: Background & Aims Chronic hepatitis D virus (HDV) often leads to end‐stage liver disease and hepatocellular carcinoma (HCC). Comprehensive data pertaining to large populations with HDV and HCC are missing, therefore we sought to assess the characteristics, management, and outcome of these patients, comparing them to patients with hepatitis B virus (HBV) infection. Methods We analysed the Italian Liver Cancer database focusing on patients with positivity for HBV surface antigen and anti‐HDV antibodies (HBV/HDV, n = 107) and patients with HBV infection alone ( n = 588). Clinical and oncological characteristics, treatment, and survival were compared in the two groups. Results Patients with HBV/HDV had worse liver function [Model for End‐stage Liver Disease score: 11 vs. 9, p < .0001; Child‐Turcotte‐Pugh score: 7 vs. 5, p < .0001] than patients with HBV. HCC was more frequently diagnosed during surveillance (72.9% vs. 52.4%, p = .0002), and the oncological stage was more frequently Milan‐in (67.3% vs. 52.7%, p = .005) in patients with HBV/HDV. Liver transplantation was more frequently performed in HBV/HDV than in HBV patients (36.4% vs. 9.5%), while the opposite was observed for resection (8.4% vs. 20.1%, p < .0001), and in a competing risk analysis, HBV/HDV patients had a higher probability of receiving transplantation, independently of liver function and oncological stage. A trend towards longer survival was observed in patients with HBV/HDV (50.4 vs. 44.4 months, p = .106). Conclusions In patients with HBV/HDV, HCC is diagnosed more frequently during surveillance, resulting in a less advanced cancer stage in patients with more deranged liver function than HBV alone. Patients with HBV/HDV have a heightened benefit from liver transplantation, positively influencing survival.

الإتاحة: https://doi.org/10.1111/liv.15855Test

المؤلفون: Nardone, Olga Maria, Iacucci, Marietta, Villanacci, Vincenzo, Peyrin‐Biroulet, Laurent, Ghosh, Subrata, Danese, Silvio, Parigi, Tommaso Lorenzo

المصدر: United European Gastroenterology Journal ; volume 11, issue 6, page 514-519 ; ISSN 2050-6406 2050-6414

الوصف: Background Treatment targets of ulcerative colitis (UC) have evolved to include not only endoscopic but also histologic remission. However, the concept of histological activity is still in its early days. We aimed to capture the attitudes toward UC histology and the uptake of standardized reporting of endoscopy and histology of UC in daily practice. Methods We conducted a cross‐sectional survey of physicians involved in the care of inflammatory bowel disease worldwide. The survey included 21 questions divided into three sections. The first recorded demographics, specialty, and level of experience of participants; the second covered clinical practices and attitudes toward the use and reporting of endoscopy; and the third covered histology. Results In total, 359 participants from 60 countries and all levels of experience completed the survey. UC histology was used by nearly all respondents (90.5%) for initial diagnosis, by 72% to monitor disease course, by 62.4% to determine the microscopic extension, by 59.9% to confirm deep remission when considering to stop treatment, and 42.3% to increase/optimize treatment. Nevertheless 77.2% of participants reported that no standard histological index was available in their daily practice. Instead, endoscopy reports included the Mayo Endoscopic score in 90% of cases. The majority of respondents welcomed as useful or very useful an artificial intelligence system to automate scoring of endoscopy (69%) or histology (73%). Conclusion UC histology reports are less standard than endoscopy reports, although most physicians consider histological activity useful when managing UC and would welcome artificial intelligence systems to automate endoscopic and histological scoring.

الإتاحة: https://doi.org/10.1002/ueg2.12423Test

المؤلفون: Kondili, Loreta A., Zanetto, Alberto, Quaranta, Maria Giovanna, Ferrigno, Luigina, Panetta, Valentina, Calvaruso, Vincenza, Zignego, Anna Linda, Brunetto, Maurizia R., Raimondo, Giovanni, Biliotti, Elisa, Ieluzzi, Donatella, Iannone, Andrea, Madonia, Salvatore, Chemello, Liliana, Cavalletto, Luisa, Coppola, Carmine, Morisco, Filomena, Barbaro, Francesco, Licata, Anna, Federico, Alessandro, Cerini, Federica, Persico, Marcello, Pompili, Maurizio, Ciancio, Alessia, Piscaglia, Fabio, Chessa, Luchino, Giacometti, Andrea, Invernizzi, Pietro, Brancaccio, Giuseppina, Benedetti, Antonio, Baiocchi, Leonardo, Gentile, Ivan, Coppola, Nicola, Nardone, Gerardo, Craxì, Antonio, Russo, Francesco Paolo

المصدر: United European Gastroenterology Journal ; volume 12, issue 3, page 352-363 ; ISSN 2050-6406 2050-6414

الوصف: Background & Aims Sustained virological response (SVR) by direct‐acting antivirals (DAAs) may reverse the hypercoagulable state of HCV cirrhosis and the portal vein thrombosis (PVT) risk. We evaluated the incidence and predictive factors of de novo, non‐tumoral PVT in patients with cirrhosis after HCV eradication. Methods Patients with HCV‐related cirrhosis, consecutively enrolled in the multi‐center ongoing PITER cohort, who achieved the SVR using DAAs, were prospectively evaluated. Kaplan‐Meier and competing risk regression analyses were performed. Results During a median time of 38.3 months (IQR: 25.1–48.7 months) after the end of treatment (EOT), among 1609 SVR patients, 32 (2.0%) developed de novo PVT. A platelet count ≤120,000/μL, albumin levels ≤3.5 mg/dL, bilirubin >1.1 mg/dL, a previous liver decompensation, ALBI, Baveno, FIB‐4, and RESIST scores were significantly different ( p < 0.001), among patients who developed PVT versus those who did not. Considering death and liver transplantation as competing risk events, esophageal varices (subHR: 10.40; CI 95% 4.33–24.99) and pre‐treatment ALBI grade ≥2 (subHR: 4.32; CI 95% 1.36–13.74) were independent predictors of PVT. After HCV eradication, a significant variation in PLT count, albumin, and bilirubin ( p < 0.001) versus pre‐treatment values was observed in patients who did not develop PVT, whereas no significant differences were observed in those who developed PVT ( p > 0.05). After the EOT, esophageal varices and ALBI grade ≥2, remained associated with de novo PVT (subHR: 9.32; CI 95% 3.16–27.53 and subHR: 5.50; CI 95% 1.67–18.13, respectively). Conclusions In patients with HCV‐related cirrhosis, a more advanced liver disease and significant portal hypertension are independently associated with the de novo PVT risk after SVR.

الإتاحة: https://doi.org/10.1002/ueg2.12496Test

المؤلفون: Nucera, Bruna, Rinaldi, Fabrizio, Flore, Davide, Panebianco, Luca, Bratti, Arianna, Ferraiuolo, Imma, Nardone, Raffaele, Brigo, Francesco

المصدر: Epileptic Disorders ; volume 25, issue 5, page 791-794 ; ISSN 1294-9361 1950-6945

الوصف: Content available: Video.

الإتاحة: https://doi.org/10.1002/epd2.20139Test

المؤلفون: Pelizzaro, Filippo, Trevisani, Franco, Simeon, Vittorio, Vitale, Alessandro, Cillo, Umberto, Piscaglia, Fabio, Missale, Gabriele, Sangiovanni, Angelo, Foschi, Francesco G., Cabibbo, Giuseppe, Caturelli, Eugenio, Di Marco, Maria, Azzaroli, Francesco, Brunetto, Maurizia R., Raimondo, Giovanni, Vidili, Gianpaolo, Guarino, Maria, Gasbarrini, Antonio, Campani, Claudia, Svegliati‐Baroni, Gianluca, Giannini, Edoardo G., Mega, Andrea, Masotto, Alberto, Rapaccini, Gian Ludovico, Magalotti, Donatella, Sacco, Rodolfo, Nardone, Gerardo, Farinati, Fabio

المصدر: Liver International ; volume 43, issue 12, page 2762-2775 ; ISSN 1478-3223 1478-3231

الوصف: Background and Aims Hepatocellular carcinoma (HCC) recurrence is common in patients treated with liver resection (LR). In this study, we aimed to evaluate the incidence and preoperative predictors of non‐transplantable recurrence in patients with single HCC ≤5 cm treated with frontline LR. Methods From the Italian Liver Cancer (ITA.LI.CA) database, 512 patients receiving frontline LR for single HCC ≤5 cm were retrieved. Incidence and predictors of recurrence beyond Milan criteria (MC) and up‐to‐seven criteria were compared between patients with HCC <4 and ≥4 cm. Results During a median follow‐up of 4.2 years, the overall recurrence rate was 55.9%. In the ≥4 cm group, a significantly higher proportion of patients recurred beyond MC at first recurrence (28.9% vs. 14.1%; p < 0.001) and overall (44.4% vs. 25.2%; p < 0.001). Similar results were found considering recurrence beyond up‐to‐seven criteria. Compared to those with larger tumours, patients with HCC <4 cm had a longer recurrence‐free survival and overall survival. HCC size ≥4 cm and high alpha‐fetoprotein (AFP) level at the time of LR were independent predictors of recurrence beyond MC (and up‐to‐seven criteria). In the subgroup of patients with available histologic information ( n = 354), microvascular invasion and microsatellite lesions were identified as additional independent risk factors for non‐transplantable recurrence. Conclusions Despite the high recurrence rate, LR for single HCC ≤5 cm offers excellent long‐term survival. Non‐transplantable recurrence is predicted by HCC size and AFP levels, among pre‐operatively available variables. High‐risk patients could be considered for frontline LT or listed for transplantation even before recurrence.

الإتاحة: https://doi.org/10.1111/liv.15719Test

المؤلفون: Ianieri, Manuel Maria, De Cicco Nardone, Alessandra, Benvenga, Greta, Greco, Pierfrancesco, Pafundi, Pia Clara, Alesi, Maria Vittoria, Campolo, Federica, Lodoli, Claudio, Abatini, Carlo, Attalla El Halabieh, Miriam, Pacelli, Fabio, Scambia, Giovanni, Santullo, Francesco

المصدر: International Journal of Gynecology & Obstetrics ; volume 164, issue 1, page 277-285 ; ISSN 0020-7292 1879-3479

الوصف: Objective Surgical management of bowel endometriosis is still controversial. Recently, many authors have pointed out the potential benefits of preserving the superior rectal artery, thus ensuring better perfusion of the anastomosis. The aim of this study was to evaluate the complication rate and functional outcomes of a bowel resection technique for deep endometriosis (DE) involving a nerve‐ and vascular‐sparing approach. Methods A single‐center retrospective study was conducted by enrolling patients who underwent segmental resection of the rectus sigmoid for DE in our department between September 2019 and April 2022. Intraoperative and postoperative complications were recorded for each woman, and functional outcomes relating to the pelvic organs were assessed using validated questionnaires (Knowles‐Eccersley‐Scott‐Symptom [KESS] questionnaire and Gastro‐Intestinal Quality of Life Index [GIQLI] for bowel function, Bristol Female Lower Urinary Tract Symptoms [BFLUTS] for urinary function, and Female Sexual Function Index [FSFI] for sexual function). These were evaluated preoperatively and postoperatively after 6 months from surgery. Results Sixty‐one patients were enrolled. No patients had Clavien‐Dindo grade 3 or 4 complications, there were no rectovaginal fistulas or ureteral lesions, and in no cases was it necessary to reoperate. Temporary bladder voiding deficits were reported in 8.2% of patients, which were treated with self‐catheterizations, always resolving within 45 days of surgery. Gastrointestinal function evaluated by KESS and GIQLI improved significantly after surgery, whereas sexual function appeared to worsen, although without reaching the level of statistically significant validity. Conclusion Our vascular‐ and nerve‐sparing segmental bowel resection technique for DE had a low intraoperative and postoperative complication rate and produced an improvement in gastrointestinal function after surgery.

الإتاحة: https://doi.org/10.1002/ijgo.15019Test

المؤلفون: Kislaya, Irina, Sentís, Alexis, Starrfelt, Jostein, Nunes, Baltazar, Martínez‐Baz, Iván, Nielsen, Katrine Finderup, AlKerwi, Ala'a, Braeye, Toon, Fontán‐Vela, Mario, Bacci, Sabrina, Meijerink, Hinta, Castilla, Jesús, Emborg, Hanne‐Dorthe, Hansen, Christian Holm, Schmitz, Susanne, Van Evercooren, Izaak, Valenciano, Marta, Nardone, Anthony, Nicolay, Nathalie, Monge, Susana

المساهمون: European Centre for Disease Prevention and Control

المصدر: Influenza and Other Respiratory Viruses ; volume 17, issue 11 ; ISSN 1750-2640 1750-2659

الوصف: Background Within the ECDC‐VEBIS project, we prospectively monitored vaccine effectiveness (VE) against COVID‐19 hospitalisation and COVID‐19‐related death using electronic health registries (EHR), between October 2021 and November 2022, in community‐dwelling residents aged 65–79 and ≥80 years in six European countries. Methods EHR linkage was used to construct population cohorts in Belgium, Denmark, Luxembourg, Navarre (Spain), Norway and Portugal. Using a common protocol, for each outcome, VE was estimated monthly over 8‐week follow‐up periods, allowing 1 month‐lag for data consolidation. Cox proportional‐hazards models were used to estimate adjusted hazard ratios (aHR) and VE = (1 − aHR) × 100%. Site‐specific estimates were pooled using random‐effects meta‐analysis. Results For ≥80 years, considering unvaccinated as the reference, VE against COVID‐19 hospitalisation decreased from 66.9% (95% CI: 60.1; 72.6) to 36.1% (95% CI: −27.3; 67.9) for the primary vaccination and from 95.6% (95% CI: 88.0; 98.4) to 67.7% (95% CI: 45.9; 80.8) for the first booster. Similar trends were observed for 65–79 years. The second booster VE against hospitalisation ranged between 82.0% (95% CI: 75.9; 87.0) and 83.9% (95% CI: 77.7; 88.4) for the ≥80 years and between 39.3% (95% CI: −3.9; 64.5) and 80.6% (95% CI: 67.2; 88.5) for 65–79 years. The first booster VE against COVID‐19‐related death declined over time for both age groups, while the second booster VE against death remained above 80% for the ≥80 years. Conclusions Successive vaccine boosters played a relevant role in maintaining protection against COVID‐19 hospitalisation and death, in the context of decreasing VE over time. Multicountry data from EHR facilitate robust near‐real‐time VE monitoring in the EU/EEA and support public health decision‐making.

الإتاحة: https://doi.org/10.1111/irv.13195Test

المؤلفون: Tursi, Antonio, Piovani, Daniele, Brandimarte, Giovanni, Di Mario, Francesco, Elisei, Walter, Picchio, Marcello, Allegretta, Leonardo, Annunziata, Maria Laura, Bafutto, Mauro, Bassotti, Gabrio, Bianco, Maria Antonia, Colucci, Raffaele, Conigliaro, Rita, Dumitrascu, Dan L., Escalante, Ricardo, Ferrini, Luciano, Forti, Giacomo, Franceschi, Marilisa, Graziani, Maria Giovanna, Lammert, Frank, Latella, Giovanni, Maconi, Giovanni, Compare, Debora, Nardone, Gerardo, Camara De Castro Oliveira, Lucia, Oliveira, Enio Chaves, Papa, Alfredo, Papagrigoriadis, Savvas, Pietrzak, Anna, Pontone, Stefano, Poskus, Tomas, Pranzo, Giuseppe, Reichert, Matthias Christian, Rodinò, Stefano, Regula, Jaroslaw, Scaccianoce, Giuseppe, Scaldaferri, Franco, Vassallo, Roberto, Zampaletta, Costantino, Zullo, Angelo, Spaziani, Erasmo, Bonovas, Stefanos, Danese, Silvio

المصدر: United European Gastroenterology Journal ; volume 11, issue 7, page 642-653 ; ISSN 2050-6406 2050-6414

الوصف: Background and Aims The Diverticular Inflammation and Complication Assessment (DICA) classification and the Combined Overview on Diverticular Assessment (CODA) were found to be effective in predicting the outcomes of Diverticular Disease (DD). We ascertain whether fecal calprotectin (FC) can further aid in improving risk stratification. Methods A three‐year international, multicentre, prospective cohort study was conducted involving 43 Gastroenterology and Endoscopy centres. Survival methods for censored observations were used to estimate the risk of acute diverticulitis (AD) in newly diagnosed DD patients according to basal FC, DICA, and CODA. The net benefit of management strategies based on DICA, CODA and FC in addition to CODA was assessed with decision curve analysis, which incorporates the harms and benefits of using a prognostic model for clinical decisions. Results At the first diagnosis of diverticulosis/DD, 871 participants underwent FC measurement. FC was associated with the risk of AD at 3 years (HR per each base 10 logarithm increase: 3.29; 95% confidence interval, 2.13–5.10) and showed moderate discrimination (c‐statistic: 0.685; 0.614–0.756). DICA and CODA were more accurate predictors of AD than FC. However, FC showed high discrimination capacity to predict AD at 3 months, which was not maintained at longer follow‐up times. The decision curve analysis comparing the combination of FC and CODA with CODA alone did not clearly indicate a larger net benefit of one strategy over the other. Conclusions FC measurement could be used as a complementary tool to assess the immediate risk of AD. In all other cases, treatment strategies based on the CODA score alone should be recommended.

الإتاحة: https://doi.org/10.1002/ueg2.12369Test

المؤلفون: Musa, Sanjin, Catovic Baralija, Elma, Ivey Sawin, Veronica, Nardone, Anthony, Palo, Mirza, Skocibusic, Sinisa, Blazevic, Mia, Cilovic Lagarija, Seila, Ahmetovic‐Karic, Gorana, Ljuca, Alma, Dostovic‐Halilovic, Sanela, Nedic, Rozalija, Subissi, Lorenzo, Ibrahim, Rawi, Boshevska, Golubinka, Bergeri, Isabel, Pebody, Richard, Vaughan, Aisling

المصدر: Influenza and Other Respiratory Viruses ; volume 17, issue 8 ; ISSN 1750-2640 1750-2659

الوصف: Background Sarajevo Canton in the Federation of Bosnia and Herzegovina has recorded several waves of high SARS‐CoV‐2 transmission and has struggled to reach adequate vaccination coverage. We describe the evolution of infection‐ and vaccine‐induced SARS‐CoV‐2 antibody response and persistence. Methods We conducted repeated cross‐sectional analyses of blood donors aged 18–65 years in Sarajevo Canton in November–December 2020 and 2021. We analyzed serum samples for anti‐nucleocapsid (anti‐N) and anti‐spike (anti‐S) antibodies. To assess immune durability, we conducted longitudinal analyses of seropositive participants at 6 and 12 months. Results One thousand fifteen participants were included in Phase 1 (November–December 2020) and 1152 in Phase 2 (November–December 2021). Seroprevalence increased significantly from 19.2% (95% CI: 17.2%–21.4%) in Phase 1 to 91.6% (95% CI: 89.8%–93.1%) in Phase 2. Anti‐S IgG titers were significantly higher among vaccinated (58.5%) than unvaccinated infected participants across vaccine products ( p < 0.001), though highest among those who received an mRNA vaccine. At 6 months, 78/82 (95.1%) participants maintained anti‐spike seropositivity; at 12 months, 58/58 (100.0%) participants were seropositive, and 33 (56.9%) had completed the primary vaccine series within 6 months. Among 11 unvaccinated participants who were not re‐infected at 12 months, anti‐S IgG declined from median 770.1 (IQR 615.0–1321.7) to 290.8 (IQR 175.7–400.3). Anti‐N IgG antibodies waned earlier, from 35.4% seropositive at 6 months to 24.1% at 12 months. Conclusions SARS‐CoV‐2 seroprevalence increased significantly over 12 months from end of 2020 to end of 2021. Although individuals with previous infection may have residual protection, COVID‐19 vaccination is vital to strengthening population immunity.

الإتاحة: https://doi.org/10.1111/irv.13182Test